Janine M Lombard1,2,3, Nicholas Zdenkowski4,5,6, Kathy Wells7, Corinna Beckmore6, Linda Reaby6, John F Forbes4,5,6, Jacquie Chirgwin5,6,8. 1. Calvary Mater Newcastle, Newcastle, NSW, Australia. Janine.lombard@calvarymater.org.au. 2. University of Newcastle, Newcastle, NSW, Australia. Janine.lombard@calvarymater.org.au. 3. Australia and New Zealand Breast Cancer Trials Group, Newcastle, NSW, Australia. Janine.lombard@calvarymater.org.au. 4. Calvary Mater Newcastle, Newcastle, NSW, Australia. 5. University of Newcastle, Newcastle, NSW, Australia. 6. Australia and New Zealand Breast Cancer Trials Group, Newcastle, NSW, Australia. 7. Breast Cancer Network Australia, Newcastle, Vic, Australia. 8. Monash University, Newcastle, Vic, Australia.
Abstract
BACKGROUND: Aromatase inhibitor induced musculoskeletal syndrome is experienced by approximately half of women taking aromatase inhibitors, impairing quality of life and leading some to discontinue treatment. Evidence for effective treatments is lacking. We aimed to understand the manifestations and impact of this syndrome in the Australian breast cancer community, and strategies used for its management. METHODS: A survey invitation was sent to 2390 members of the Breast Cancer Network Australia Review and Survey Group in April 2014. The online questionnaire included 45 questions covering demographics, aromatase inhibitor use, clinical manifestations and risk factors for the aromatase inhibitor musculoskeletal syndrome, reasons for treatment discontinuation and efficacy of interventions used. RESULTS: Aromatase inhibitor induced musculoskeletal syndrome was reported by 302 (82 %) of 370 respondents. Twenty-seven percent had discontinued treatment for any reason and of these, 68 % discontinued because of the musculoskeletal syndrome. Eighty-one percent had used at least one intervention from the following three categories to manage the syndrome: doctor prescribed medications, over-the-counter/complementary medicines or alternative/non-drug therapies. Anti-inflammatories, paracetamol (acetaminophen) and yoga were most successful in relieving symptoms in each of the respective categories. Almost a third of respondents reported that one or more interventions helped prevent aromatase inhibitor discontinuation. However, approximately 20 % of respondents found no intervention effective in any category. CONCLUSION: We conclude that aromatase inhibitor induced musculoskeletal syndrome is a significant issue for Australian women and is an important reason for treatment discontinuation. Women use a variety of interventions to manage this syndrome; however, their efficacy appears limited.
BACKGROUND: Aromatase inhibitor induced musculoskeletal syndrome is experienced by approximately half of women taking aromatase inhibitors, impairing quality of life and leading some to discontinue treatment. Evidence for effective treatments is lacking. We aimed to understand the manifestations and impact of this syndrome in the Australian breast cancer community, and strategies used for its management. METHODS: A survey invitation was sent to 2390 members of the Breast Cancer Network Australia Review and Survey Group in April 2014. The online questionnaire included 45 questions covering demographics, aromatase inhibitor use, clinical manifestations and risk factors for the aromatase inhibitor musculoskeletal syndrome, reasons for treatment discontinuation and efficacy of interventions used. RESULTS: Aromatase inhibitor induced musculoskeletal syndrome was reported by 302 (82 %) of 370 respondents. Twenty-seven percent had discontinued treatment for any reason and of these, 68 % discontinued because of the musculoskeletal syndrome. Eighty-one percent had used at least one intervention from the following three categories to manage the syndrome: doctor prescribed medications, over-the-counter/complementary medicines or alternative/non-drug therapies. Anti-inflammatories, paracetamol (acetaminophen) and yoga were most successful in relieving symptoms in each of the respective categories. Almost a third of respondents reported that one or more interventions helped prevent aromatase inhibitor discontinuation. However, approximately 20 % of respondents found no intervention effective in any category. CONCLUSION: We conclude that aromatase inhibitor induced musculoskeletal syndrome is a significant issue for Australian women and is an important reason for treatment discontinuation. Women use a variety of interventions to manage this syndrome; however, their efficacy appears limited.
Entities:
Keywords:
Aromatase inhibitor; Arthralgia; Arthritis; Early breast cancer; Interventions; Myalgia
Authors: A Lintermans; B Van Calster; M Van Hoydonck; S Pans; J Verhaeghe; R Westhovens; N L Henry; H Wildiers; R Paridaens; A S Dieudonné; K Leunen; L Morales; K Verschueren; D Timmerman; L De Smet; I Vergote; M R Christiaens; P Neven Journal: Ann Oncol Date: 2011-01-27 Impact factor: 32.976
Authors: Alan S Coates; Aparna Keshaviah; Beat Thürlimann; Henning Mouridsen; Louis Mauriac; John F Forbes; Robert Paridaens; Monica Castiglione-Gertsch; Richard D Gelber; Marco Colleoni; István Láng; Lucia Del Mastro; Ian Smith; Jacquie Chirgwin; Jean-Marie Nogaret; Tadeusz Pienkowski; Andrew Wardley; Erik H Jakobsen; Karen N Price; Aron Goldhirsch Journal: J Clin Oncol Date: 2007-01-02 Impact factor: 44.544
Authors: N Lynn Henry; Faouzi Azzouz; Zereunesay Desta; Lang Li; Anne T Nguyen; Suzanne Lemler; Jill Hayden; Karineh Tarpinian; Elizabeth Yakim; David A Flockhart; Vered Stearns; Daniel F Hayes; Anna Maria Storniolo Journal: J Clin Oncol Date: 2012-02-13 Impact factor: 44.544
Authors: R C Coombes; L S Kilburn; C F Snowdon; R Paridaens; R E Coleman; S E Jones; J Jassem; C J H Van de Velde; T Delozier; I Alvarez; L Del Mastro; O Ortmann; K Diedrich; A S Coates; E Bajetta; S B Holmberg; D Dodwell; E Mickiewicz; J Andersen; P E Lønning; G Cocconi; J Forbes; M Castiglione; N Stuart; A Stewart; L J Fallowfield; G Bertelli; E Hall; R G Bogle; M Carpentieri; E Colajori; M Subar; E Ireland; J M Bliss Journal: Lancet Date: 2007-02-17 Impact factor: 79.321
Authors: Dawn L Hershman; Theresa Shao; Lawrence H Kushi; Donna Buono; Wei Yann Tsai; Louis Fehrenbacher; Marilyn Kwan; Scarlett Lin Gomez; Alfred I Neugut Journal: Breast Cancer Res Treat Date: 2010-08-28 Impact factor: 4.872
Authors: A Lintermans; K Van Asten; H Wildiers; A Laenen; R Paridaens; C Weltens; J Verhaeghe; D Vanderschueren; A Smeets; E Van Limbergen; K Leunen; M R Christiaens; P Neven Journal: Breast Cancer Res Treat Date: 2014-05-11 Impact factor: 4.872
Authors: Cary A Presant; Linda Bosserman; Traci Young; Mayank Vakil; Richard Horns; Gargi Upadhyaya; Behnam Ebrahimi; Christina Yeon; Frank Howard Journal: Clin Breast Cancer Date: 2007-10 Impact factor: 3.225
Authors: Jack Cuzick; Ivana Sestak; John F Forbes; Mitch Dowsett; Jill Knox; Simon Cawthorn; Christobel Saunders; Nicola Roche; Robert E Mansel; Gunter von Minckwitz; Bernardo Bonanni; Tiina Palva; Anthony Howell Journal: Lancet Date: 2013-12-12 Impact factor: 79.321
Authors: Arlene Chan; R De Boer; A Gan; P Willsher; R Martin; Y Zissiadis; K Miller; A Bauwens; D Hastrich Journal: Support Care Cancer Date: 2017-07-09 Impact factor: 3.603
Authors: Kerstin Faravel; Marie-Eve Huteau; Marta Jarlier; Hélène de Forges; Laetitia Meignant; Pierre Senesse; Joanna Norton; William Jacot; Anne Stoebner Journal: Integr Cancer Ther Date: 2021 Jan-Dec Impact factor: 3.279
Authors: C C Hack; L Häberle; S Y Brucker; W Janni; B Volz; C R Loehberg; A D Hartkopf; C-B Walter; G Baake; A Fridman; W Malter; R Wuerstlein; N Harbeck; O Hoffmann; S Kuemmel; B Martin; C Thomssen; H Graf; C Wolf; M P Lux; C M Bayer; C Rauh; K Almstedt; P Gass; F Heindl; T Brodkorb; L Willer; C Lindner; H-C Kolberg; P Krabisch; M Weigel; D Steinfeld-Birg; A Kohls; C Brucker; V Schulz; G Fischer; V Pelzer; B Rack; M W Beckmann; T Fehm; A Rody; N Maass; A Hein; P A Fasching; N Nabieva Journal: Breast Date: 2020-01-08 Impact factor: 4.380